NuVision is managed by an expert team of directors encompassing essential skills of business development, clinical ophthalmic surgery, medical affairs, GMP manufacturing and research and development. Together we create a unique dynamic that will enable the company to grow and evolve to redefine sight saving biotherapies.
Mr Peter Dines
As a highly successful entrepreneur and investor, Peter heads up Life Science Investments at Mercia Fund Management.
He has over 20 years’ experience in the healthcare sector, where during this period, Peter founded Surgi C Group which he grew and sold to a private equity backed company. Other key healthcare positions held include Cisiv, Diagnostic World and Spring Active.
Andrew Hopkinson, PhD, is the Chief Executive Officer, founder and visionary of NuVision. Andrew has 15 years’ translational research expertise in ophthalmic regenerative medicine as the Principal Research Fellow at Nottingham Centre For Eye research, which is part of Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham.
During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo processing and Omnigen. He continues to drive ground breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative Biotherapies for NuVision.
During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed 4 patents.
Dr Andrew Hopkinson
Mr Bryan Lister
Bryan Lister is the Chief Operating Officer of NuVision. Bryan has spent more than 25 years working in sales, marketing, operational and regulatory functions for major healthcare companies including ICI, Novartis, Grifols UK and Fresenius-Kabi.
Over the last 5 years, Bryan has focused upon the academic-industrial healthcare biotech interface working on new product development projects associated with wound healing. This has led to Bryan working with Dr Andrew Hopkinson to productionise and commercialise NuVision Biotherapies’ portfolio.
Bryan holds a BSc (Hons) in Biology and Biotechnology, a CIM Diploma in Marketing and an MBA from the University of Bradford School of Management.
Helen Shaw is a qualified doctor with over 20 years’ experience as a medical professional in the pharmaceutical industry. She has a proven track record in providing strategic direction and focus in product development and innovation and her experience covers all drug and device classifications, and all stages of development and marketing, in a global arena.
Helen’s expertise is in providing leadership and strategic direction at Board level, fostering excellent relationships with key stakeholders and regulatory authorities and translating technical and regulatory needs into clear development programmes.
Helen is Chairman of NuVision Biotherapies, non-executive director of ModeDx, (providing point of care real time diagnostics for bowel cancer) and was a non-executive director with Syntopix (skincare), Zilico Ltd (cervical cancer diagnostics) and Auralis Ltd (critical care and paediatric medicine).
Dr Helen Shaw
Sales & Marketing Director
Kate has 20 years’ experience of working in Health and Social Care. With a focus on innovative products and services. She has worked across the NHS, public, private and third sectors to produce patient-centred, high quality, outcome based services and facilitate the market entry and growth of new products.
Kate’s experience covers: Product launches, writing winning bids, working with commissioners and designing, selling and mobilization of new integrated services. She has a clear focus on outcomes and what is required to demonstrate them, with a view to extension and expansion.
For the last 2 years Kate has supported multiple companies as managing director of Pym’s Consultancy Ltd, an independent consultancy for healthcare market access.
Awards for Pym’s Consultancy Ltd:
Medilink East Midlands Start-Up Award finalist 2014
Medilink East Midlands Start-Up Award winner 2015
María J. Mendoza is the Process Development Officer at NuVision. Her experience includes molecular, cell biology and immunology research. Graduated from the University of Nottingham with a MSc. in Stem Cell Technology, she has knowledge of regenerative therapies and translational technologies. As an intern in NuVision, Maria has been involved in the translation and implementation of OmnigenTM manufacture into clinical standards. She oversees OmnigenTM manufacture, process development and translation of new research technologies into clinical standards following the HTA requirements.
Process Development Officer
Manufacturing Technical Manager
Owen McIntosh is the Manufacturing Technical Manager at NuVision Biotherapies. Alongside his work at NuVision, he has worked at the University of Nottingham for five years.
Owen is responsible for the Tissue Processing Facility in which Omnigen is manufactured, as well as the equipment and consumables within it. He assists in Product Development at NuVision and the University.
Dr Emily Britchford is the Research and Development Officer at NuVision. She has several years’ experience in both academic and applied scientific research. Emily has recently graduated with a PhD in Tissue Engineering at the University of Nottingham as part of the EPSRC doctoral training program in regenerative medicine.
Emily has a dual role also working as a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham. Her research interests focus on the development of Omnigen application for acute ocular surface trauma.
Dr Emily Britchford
Research and Development Officer
Affiliate in International Regulatory Frameworks
Rachel Hampson has joined the NuVision team as part of a University of Nottingham internship. Rachel has been working on the processing and manufacturing of Omnigen in the laboratory as well as engaging in the regulatory functions of the business with regards to distribution of Omnigen across the globe.
Rachel holds a BSc (Hons) in Biology and an MSc in Clinical Microbiology, both from the University of Nottingham.
Rebecca has a degree in Bioveterinary Science from The University of Liverpool.
She has gained experience in sales, marketing and administration through
She will be product specialist for veterinary customers as well as being
involved in manufacturing Omnigen and maintaining the Tissue Processing Facility.
Adrian Del Arenal Martin
Adrian Del Arenal Martin has joined the team as a Intern Manufacturing Technician. He is a Biotechnology Engineer with experience in recombinant protein bioprocessing. He graduated from the University of Nottingham with a MSc. in Biopharmaceutics and Business and has gained start-up business knowledge as a intern SME consultant at BioCity.
Adrian will be working on clinical sales as well as manufacturing our products.
Nick Shaw is NuVision’s Office Manager and responsible for processing customer orders, dispatching Omnigen stock, customer service, invoicing, accounts, banking and generally keeping the office side of things running smoothly.
He has over 20 years’ experience in the commercial radio sector handling customer orders and broadcast schedules. At NuVision his customer-focussed skills help to deliver the best possible service to all our clients.
Nick usually cycles the 25-mile round trip from his home to the NuVision office, condemning his colleagues to the unwelcome sight of him in tight lycra. Even Omnigen can’t cure that.